Gómez-Esteban Juan Carlos, Zarranz Juan J, Velasco Fernando, Lezcano Elena, Lachen M C, Rouco Idoia, Barcena Joseba, Boyero Sabas, Ciordia Roberto, Allue Isidro
Neurology Service, Hospital of Cruces, Baracaldo, Vizcaya, Spain.
Clin Neuropharmacol. 2005 May-Jun;28(3):111-4. doi: 10.1097/01.wnf.0000164297.91643.ff.
Twelve patients with Parkinson disease and psychosis were included in an open-label 12-week trial of ziprasidone. Two patients withdrew from the treatment because of adverse effects. The remaining 10 patients reported a significant improvement in psychiatric symptoms. Altogether, there was no deterioration of motor symptoms (UPDRS III score: basal 40.4 +/- 11.1, first month 41.1 +/- 10.8; final visit, 37.7 +/- 13.3). Two patients (20%) suffered a slight deterioration in motor symptoms and another patient suffered deterioration of gait. No analytic alterations or serious adverse effects that could limit the use of ziprasidone were observed. Although controlled trials are needed, the findings suggest that ziprasidone may be effective in parkinsonian patients with psychosis.
12名患有帕金森病和精神病的患者参与了一项为期12周的齐拉西酮开放标签试验。2名患者因不良反应退出治疗。其余10名患者报告精神症状有显著改善。总体而言，运动症状没有恶化（统一帕金森病评定量表III评分：基线时40.4±11.1，第一个月41.1±10.8；最后一次随访时37.7±13.3）。2名患者（20%）运动症状略有恶化，另1名患者步态恶化。未观察到可能限制齐拉西酮使用的分析性改变或严重不良反应。尽管需要对照试验，但研究结果表明，齐拉西酮可能对患有精神病的帕金森病患者有效。
